File Rouge Capital backs Vivian Lab: redefining menopause and longevity care

Women entering midlife have long been underserved by healthcare systems that treat menopause as a secondary issue rather than a central life stage. The result has been fragmented care, limited proactive strategies, and a lack of resources, even though more than half of the world’s population will experience menopause, often while balancing careers and family life.

At the same time, advances in AI and biomarker science are opening new opportunities to predict, personalize, and prevent health challenges in ways that were unimaginable a decade ago. This intersection of unmet need and transformative technology is where Vivian Lab is making its impact, with support from Fil Rouge Capital.

A digital-first approach to menopause and longevity

Vivian Lab is developing what it calls the world’s first AI-native menopause and longevity platform. Designed for women starting around age 40, the platform offers comprehensive support for physical, mental, and emotional wellbeing. Using predictive biomarkers, lifestyle tracking, and an AI engine grounded in clinical research, Vivian Lab provides personalized guidance for managing symptoms such as sleep disruption and mood changes, while also helping users anticipate long-term risks related to heart health, bone density, and cognitive decline.

What sets Vivian Lab apart is its integration into the broader healthcare ecosystem. Unlike most consumer health apps, it connects directly with doctors, clinics, hospitals, and insurers. This ensures that users receive not just recommendations but continuous, medically credible care that bridges the gap between self-managed wellness and clinical support.

A major opportunity in an underserved market

Women over 40 make up one of the largest and fastest-growing demographics worldwide, driving trillions in spending across healthcare, insurance, and wellness. Yet most existing solutions remain reactive, isolated, and stigmatized. Vivian Lab aims to change that by becoming the foundation for global menopause and longevity care.

The team driving the vision

Fil Rouge Capital’s decision to invest in Vivian Lab reflects both the scale of the opportunity and the strength of its leadership team. Founder and CEO Gina Tiriakidou has a proven track record in scaling technology ventures from small beginnings into global companies. She is joined by lifelong friends and co-founders Elena Skoura and Olga Skouteli, who bring deep expertise in healthcare and HR. Their long-standing collaboration and shared mission give Vivian Lab a rare combination of trust, alignment, and skill.

With Fil Rouge Capital’s backing, Vivian Lab is not just building a product but creating a movement that empowers women with the tools, knowledge, and care they deserve as they navigate midlife and beyond.

Fil Rouge Capital’s support highlights a shared belief in a future where menopause and longevity care are recognized as essential parts of women’s health, not an afterthought.

Source: https://www.linkedin.com/pulse/our-investment-vivian-lab-redefining-menopause-longevity-u2xkf